View in EDS

Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.

Saved in:
Bibliographic Details
Title: Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Authors: Gil-Rojas Y; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia. Electronic address: yaneth@neuroeconomix.com., Lasalvia P; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Hernández F; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Castañeda-Cardona C; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Castrillón-Correa J; Novartis de Colombia S.A., Bogotá, Colombia., Herrera D; Novartis de Colombia S.A., Bogotá, Colombia., Rosselli D; Faculty of Medicine, Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Hospital San Ignacio, Bogotá, Colombia.
Source: Value in health regional issues [Value Health Reg Issues] 2021 Dec; Vol. 26, pp. 182-190. Date of Electronic Publication: 2021 Oct 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34673349
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gil-Rojas+Y%22">Gil-Rojas Y</searchLink>; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia. Electronic address: yaneth@neuroeconomix.com.<br /><searchLink fieldCode="AU" term="%22Lasalvia+P%22">Lasalvia P</searchLink>; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Hernández+F%22">Hernández F</searchLink>; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Castañeda-Cardona+C%22">Castañeda-Cardona C</searchLink>; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Castrillón-Correa+J%22">Castrillón-Correa J</searchLink>; Novartis de Colombia S.A., Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Herrera+D%22">Herrera D</searchLink>; Novartis de Colombia S.A., Bogotá, Colombia.<br /><searchLink fieldCode="AU" term="%22Rosselli+D%22">Rosselli D</searchLink>; Faculty of Medicine, Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Hospital San Ignacio, Bogotá, Colombia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101592642%22">Value in health regional issues</searchLink> [Value Health Reg Issues] 2021 Dec; Vol. 26, pp. 182-190. <i>Date of Electronic Publication: </i>2021 Oct 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101592642 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2212-1102 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222121099%22">22121099 </searchLink><i>NLM ISO Abbreviation: </i>Value Health Reg Issues <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34673349
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vhri.2021.04.008
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 182
    Titles:
      – TitleFull: Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gil-Rojas Y
      – PersonEntity:
          Name:
            NameFull: Lasalvia P
      – PersonEntity:
          Name:
            NameFull: Hernández F
      – PersonEntity:
          Name:
            NameFull: Castañeda-Cardona C
      – PersonEntity:
          Name:
            NameFull: Castrillón-Correa J
      – PersonEntity:
          Name:
            NameFull: Herrera D
      – PersonEntity:
          Name:
            NameFull: Rosselli D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2212-1102
          Numbering:
            – Type: volume
              Value: 26
          Titles:
            – TitleFull: Value in health regional issues
              Type: main
ResultId 1